---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-002909"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-01-26T23:59:59+00:00"
generated_at: "2026-06-20T08:47:04.269391+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics CMO Dr. Roger Sidhu resigns effective Jan 31, 2023

## Summary
- Dr. Roger Sidhu, Chief Medical Officer, resigned on Jan 20, 2023 with effective date Jan 31, 2023.
- No replacement or interim CMO has been announced in the filing.
- Departure is effective immediately at the end of January 2023.

## SEC filing metadata
- accession: 0001140361-23-002909
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-01-26T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123002909/0001140361-23-002909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123002909/brhc10046926_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-002909
- JSON: https://secwatch.observer/filing/0001140361-23-002909.json
- Plain text: https://secwatch.observer/filing/0001140361-23-002909.txt

## Key facts
- Executive change
  Dr. Roger Sidhu resigned as Chief Medical Officer at Ernexa Therapeutics Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On January 20, 2023, Dr. Roger Sidhu, Chief Medical Officer of Eterna Therapeutics Inc., a Delaware corporation, delivered his notice of resignation, with such resignation becoming effective on January 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123002909/0001140361-23-002909-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.